Pasireotide Diaspartate

19 interactions 1 explained in plain English

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Acarbose Nateglinide Insulin Glulisine (Rdna Origin) Injection Dapagliflozin Dulaglutide Injection Miglitol

19 Major

All (19) Major (19)

Major

Pasireotide Diaspartate Acarbose Prandase® Explained An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Alogliptin Nesina An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Canagliflozin Invokana An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Dapagliflozin Farxiga An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Dulaglutide Injection Trulicity An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Empagliflozin Glyxambi® (as a combination product containing Empagliflozin and Linagliptin) An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Ertugliflozin Steglatro An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Exenatide Injection Bydureon An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Glimepiride Amaryl An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Glipizide Glucotrol An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Insulin Degludec (Rdna Origin) Injection Ryzodeg® (as a combination product containing Insulin Degludec and Insulin Aspart) An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Insulin Detemir (Rdna Origin) Injection Levemir An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Insulin Glulisine (Rdna Origin) Injection Apidra An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Linagliptin Tradjenta An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Liraglutide Injection Saxenda An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Lixisenatide Injection Adlyxin® An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Metformin Fortamet® An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Miglitol Glyset® An increased risk of hypoglycemia and impaired glucose regulation Details Pasireotide Diaspartate Nateglinide Starlix® An increased risk of hypoglycemia and impaired glucose regulation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.